2023 M&A Annual Review 25 Morrison Foerster advised Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, on its acquisition of Orchard Therapeutics plc, a UK-based, Nasdaq-listed, global gene therapy leader. The acquisition allows Kyowa Kirin to maximize the value of Libmeldy®, intended for eligible patients with early onset metachromatic leukodystrophy, and efficiently accelerate the development of Orchard Therapeutics’ next-inline treatments for Sanfilippo syndrome, as well as its other early research programs, including a severe, genetic form of Crohn’s disease and frontotemporal dementia.
RkJQdWJsaXNoZXIy NTU5OTQ5